Mir con

MiR‐26a‐5p mimics, miR‐29a‐3p mimics, and negative control oligonucleotides (miR‐CON) were purchased from Sigma (#HMI0415, #HMC0434, #HMC0002, respectively). Small interfering pool RNA of LIN28B, RAN, and control RNA (siLIN28B, siRAN, siCon; five siRNAs per pool) were purchased from Santa Cruz Biotechnology (#SC‐105614, #SC‐36382, #SC‐37007, respectively). LIN28B and AURKA plasmids were purchased from Addgene (#51375 and #20427, respectively). Luciferase reporter gene plasmids, including wild‐type AURKA 3′‐UTR, wild‐type LIN28B 3′‐UTR, and their seed mutants, were synthesized and subcloned into pmirGLO vectors, which were confirmed by sequencing.

The full length sequences of linc00472 were amplified by PCR and constructed into pcDNA3.1 vector (Invitrogen) to form pcDNA-linc00472 overexpression plasmid. Then the putative binding sites in the pcDNA-linc00472 were mutant to generate pcDNA-linc00472-MUT plasmid. miR-141 mimic and its scramble control (miR-con) along with miR-141 inhibitor (anti-miR-141) and its scramble control (anti-miR-con) were purchased from Sigma-Aldrich (St. Louis). Linc00472 small interference RNA (si-linc00472) and its scramble control (si-con) together with the siRNA of PDCD4 (si-PDCD4) and its scramble control (si-con) were synthesized by GenePharma Co., Ltd (Shanghai, China). Then, 100 pmol oligonucleotides or 3 μg plasmids were transfected into cells using Lipofectamine 2000 reagent (Invitrogen) referring to the manufacturer's instructions. The amplification primers and endonucleases were listed in Table 1.